Due to SMA resulting from low levels of SMN protein, new treatment strategies mainly revolve around methods of increasing SMN protein levels through modifying SMN2 gene splicing or gene replacement therapy [9]. Here, SMN2 is linked to proximal spinal muscular atrophy.